Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)

Trial Profile

A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms CLEAR
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Apr 2019 Results of post hoc analysis of two Phase 3 RCTs, FIXTURE [NCT01358578] and CLEAR [NCT02074982] determining stability of response to secukinumab,and changes in efficacy in individual patients published in the British Journal of Dermatology
    • 14 Nov 2018 Results of a 52 week cost per responder analysis from the Portuguese payer perspective using response rates data from this trial of secukinumab versus ustekinumab, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 05 Feb 2018 Results of pooled post hoc analysis of ERASURE, FIXTURE and CLEAR trials evaluating the efficacy and safety of secukinumab published in the Drugs and Aging
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top